Truist Financial’s Aethlon Medical AEMD Stock Holding History

Truist Financial’s Portfolio AEMD Stock Details AEMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-14	Closed	-$7K	–	2555
2022 Q3	$7K	Hold	14	–	–	﹤0.01%	2499
2022 Q2	$13K	Buy	+14	New	+$13K	﹤0.01%	2615

Other funds holding AEMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

AFGAS

Allegiance Financial Group Advisory Services Vienna, Virginia $503M AUM 22.39% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Truist Financial's AEMD Position: Q4 2022 in Review

Truist Financial sold out of Aethlon Medical (AEMD) in Q4 2022, closing a stake of 14 shares — an estimated $7K sold.

Truist Financial first reported a position in AEMD in Q2 2022 and held it in 2 quarters. The position peaked at $13K in Q2 2022. 27 funds tracked by Wall St. Rank hold AEMD as of Q4 2022.

Truist Financial reported no remaining Aethlon Medical position as of Q4 2022 after selling out during the quarter.
Truist Financial sold 14 Aethlon Medical shares in Q4 2022, an estimated $7K.
Truist Financial first reported a position in Aethlon Medical in Q2 2022 and held it in 2 quarters.
Truist Financial's Aethlon Medical position peaked at $13K in Q2 2022.
27 funds tracked by Wall St. Rank held Aethlon Medical as of Q4 2022.

Based on Truist Financial's 13F filing for Q4 2022, filed 17 Feb 2023.